Ebumab Sandbox ApS: Financial statements 2025
CVR: 43575627
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Ebumab Sandbox ApS (CVR 43575627) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -12,630 and a net result of DKK -11,150 compared with DKK -7,800 the year before. Equity in the 2025 report amounted to DKK 15,192. The solvency ratio was 100%.
- Gross Profit
- DKK -12,630
- Profit/Loss
- DKK -11,150
- Equity
- DKK 15,192
- Total Assets
- DKK 15,192
- Employees
- 0
Official annual report
How creditworthy is Ebumab Sandbox ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Ebumab Sandbox ApS has published its annual report for 2024. Gross profit came to DKK -10,000, and the net result was DKK -7,800.
As of February 25, 2025, Beierholm Godkendt Revisionspartnerselskab has been appointed auditor of Ebumab Sandbox ApS.
As of February 25, 2025, Slotsgade Revision ApS has stepped down as auditor of Ebumab Sandbox ApS.
About Ebumab Sandbox ApS
Ebumab Sandbox ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2022. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Hans Heugh Wandall and Johan Henrik Faber. The board consists of Thomas Dal Stenfeldt Batchelor (chair), Hans Heugh Wandall, Johan Henrik Faber and Søren Erik Bjørn. The company is owned by Ebumab Holding ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -12,630 and a net result of DKK -11,150 compared with DKK -7,800 the year before. Equity in the 2025 report amounted to DKK 15,192.